The group's principal activity is the research and development of drug delivery systems and technology. Its current focus is the development of its proprietary technology for the administration of formulations of large molecule drugs to the oral (Buccal) cavity using a hand-held aerosol applicator. In Sep-2003, the group commenced a 90 day study in 80 type 2 diabetic patients with poorly controlled blood glucose. The group continues to conduct limited clinical trials in the United States and other countries. The group is in development stage. On 08-Aug-2003, the group acquired Antigen Express Inc.
